-+ 0.00%
-+ 0.00%
-+ 0.00%

Transgene First-Nine-Month 2026 Operating Income Falls 30% to €4.3 Million

PUBT·11/09/2026 16:46:04
Listen to the news
Transgene First-Nine-Month 2026 Operating Income Falls 30% to €4.3 Million
  • Transgene’s operating income fell 30% year over year to €4.3 million in the first nine months of 2026.
  • Cash, cash equivalents and other current financial assets dropped 25% to €84.3 million at September 30, 2026, from December 31, 2025.
  • Nine-month cash burn rose to €29.5 million; financial visibility extends through early 2028 under current plans.
  • TG4050 sustained 100% disease-free survival after more than three years of follow-up in its Phase 1 head and neck cancer study.
  • Phase 2 topline results for TG4050 are expected by the end of Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091145PRIMZONEFULLFEED1001302669) on November 09, 2026, and is solely responsible for the information contained therein.